Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ATHX vs. PTN, CANF, VCNX, GRTX, ADXS, ASLN, BPTH, ATXI, EVFM, and OGENShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Palatin Technologies (PTN), Can-Fite BioPharma (CANF), Vaccinex (VCNX), Galera Therapeutics (GRTX), Ayala Pharmaceuticals (ADXS), ASLAN Pharmaceuticals (ASLN), Bio-Path (BPTH), Avenue Therapeutics (ATXI), Evofem Biosciences (EVFM), and Oragenics (OGEN). Athersys vs. Its Competitors Palatin Technologies Can-Fite BioPharma Vaccinex Galera Therapeutics Ayala Pharmaceuticals ASLAN Pharmaceuticals Bio-Path Avenue Therapeutics Evofem Biosciences Oragenics Athersys (NASDAQ:ATHX) and Palatin Technologies (NYSE:PTN) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Do institutionals & insiders believe in ATHX or PTN? 19.4% of Athersys shares are held by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are held by institutional investors. 0.0% of Athersys shares are held by insiders. Comparatively, 7.1% of Palatin Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, ATHX or PTN? Palatin Technologies has higher revenue and earnings than Athersys. Palatin Technologies is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthersys$146K0.00-$72.53M-$2.03N/APalatin Technologies$350K6.99-$40.31M-$1.55-0.06 Does the media refer more to ATHX or PTN? In the previous week, Athersys' average media sentiment score of 0.00 equaled Palatin Technologies'average media sentiment score. Company Overall Sentiment Athersys Neutral Palatin Technologies Neutral Is ATHX or PTN more profitable? Company Net Margins Return on Equity Return on Assets AthersysN/A N/A -223.03% Palatin Technologies N/A N/A N/A Which has more risk and volatility, ATHX or PTN? Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. SummaryPalatin Technologies beats Athersys on 6 of the 8 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833K$785.27M$5.48B$9.57BDividend YieldN/A4.84%3.99%4.17%P/E Ratio0.001.2929.9425.14Price / SalesN/A25.43398.9486.71Price / CashN/A19.5635.9458.58Price / BookN/A6.578.105.59Net Income-$72.53M-$3.92M$3.26B$265.48M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833K$146K0.0024PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeCANFCan-Fite BioPharma2.6328 of 5 stars$0.68+1.4%$14.00+1,946.8%-71.3%$2.42M$674K-0.388Gap UpVCNXVaccinexN/A$0.83+5.7%N/A-85.2%$2.17M$388K-0.0240Upcoming EarningsGap UpGRTXGalera TherapeuticsN/A$0.02+1.8%N/A-78.5%$1.73MN/A-0.0730Upcoming EarningsADXSAyala PharmaceuticalsN/A$0.03-13.5%N/A+66.5%$1.48M$3.24M0.0020Gap DownASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330BPTHBio-Path0.554 of 5 stars$0.14flatN/A-90.3%$1.20MN/A0.0010Trending NewsAnalyst ForecastOptions VolumeATXIAvenue Therapeutics2.3596 of 5 stars$0.37-19.6%N/A-85.9%$1.18MN/A0.024Gap DownEVFMEvofem Biosciences0.9014 of 5 stars$0.01-2.2%N/A-7.1%$1.07M$11.39M-0.01120Gap DownOGENOragenics0.1353 of 5 stars$1.26flatN/A-95.4%$1.04MN/A-0.185 Related Companies and Tools Related Companies Palatin Technologies Competitors Can-Fite BioPharma Competitors Vaccinex Competitors Galera Therapeutics Competitors Ayala Pharmaceuticals Competitors ASLAN Pharmaceuticals Competitors Bio-Path Competitors Avenue Therapeutics Competitors Evofem Biosciences Competitors Oragenics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
